Antares Pharma (ATRS) Misses Q3 EPS by 32c

Antares Pharma (NASDAQ: ATRS) reported Q3 EPS of ($0.32). Revenue for the quarter came in at $3.5 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• Freedom Broker Downgrades Nucor (NUE) to Hold, 'Guides Conservative Earnings Yet Again'
• Newsom Issues Executive Order On Creation Of Ai 'kill Switch' - Bloomberg
• EMA panel backs Novartis Cosentyx for rheumatic condition in EU